<DOC>
	<DOCNO>NCT01562587</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial determine pharmacokinetics activate recombinant human factor VII ( NovoSeven® ) haemophiliac patient non-bleeding state .</brief_summary>
	<brief_title>Pharmacokinetics Single Bolus Dose NovoSeven® Paediatric Adult Patients With Haemophilia A B Non- Bleeding State</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Age 1855 year congenital haemophilia A B male severe FVIII FX deficiency +/inhibitors Age 312 year congenital haemophilia A B male record inhibitor Known hypersensitivity activate recombinant human factor VII component Known clinical relevant coagulation disease insufficiency congenital haemophilia Clinical manifestation HIV ( human immunodeficiency virus ) and/or protease inhibitor treatment Clinical manifestation active/recent bleed Administration coagulation factor preparation within 24 hour NovoSeven trial product dose administration Body Mass Index ( BMI ) outside normal range Known abuse elicit drug and/or alcohol Renal insufficiency Hepatic disease Cardiovascular disease Any disease condition , judge Investigator , could imply potential hazard patient , interfere trial participation trial outcome</criteria>
	<gender>Male</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>